- Home
- MGNX vs FVR Comparison
MGNX vs FVR Comparison
Compare MGNX & FVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- FVR
- Stock Information
- Founded
- MGNX 2000
- FVR 2016
- Country
- MGNX United States
- FVR United States
- Employees
- MGNX N/A
- FVR N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- FVR
- Sector
- MGNX Health Care
- FVR
- Exchange
- MGNX Nasdaq
- FVR NYSE
- Market Cap
- MGNX 257.3M
- FVR 302.7M
- IPO Year
- MGNX 2013
- FVR 2024
- Fundamental
- Price
- MGNX $3.23
- FVR $18.19
- Analyst Decision
- MGNX Hold
- FVR Strong Buy
- Analyst Count
- MGNX 10
- FVR 5
- Target Price
- MGNX $7.17
- FVR $22.00
- AVG Volume (30 Days)
- MGNX 465.7K
- FVR 332.8K
- Earning Date
- MGNX 11-05-2024
- FVR 02-15-2025
- Dividend Yield
- MGNX N/A
- FVR N/A
- EPS Growth
- MGNX N/A
- FVR N/A
- EPS
- MGNX N/A
- FVR N/A
- Revenue
- MGNX $141,329,000.00
- FVR $58,655,152.00
- Revenue This Year
- MGNX $174.73
- FVR N/A
- Revenue Next Year
- MGNX N/A
- FVR $18.58
- P/E Ratio
- MGNX N/A
- FVR N/A
- Revenue Growth
- MGNX 16.68
- FVR N/A
- 52 Week Low
- MGNX $2.95
- FVR $17.80
- 52 Week High
- MGNX $21.88
- FVR $19.76
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- FVR N/A
- Support Level
- MGNX $3.10
- FVR N/A
- Resistance Level
- MGNX $3.30
- FVR N/A
- Average True Range (ATR)
- MGNX 0.19
- FVR 0.00
- MACD
- MGNX 0.00
- FVR 0.00
- Stochastic Oscillator
- MGNX 25.45
- FVR 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About FVR FRONTVIEW REIT INC
FrontView REIT Inc is an internally managed net-lease REIT that is experienced in acquiring, owning, and managing out parcel properties that are net-leased to a diversified group of tenants. Its tenants include service-oriented businesses, such as restaurants, cellular stores, financial institutions, automotive stores and dealers, medical and dental providers, pharmacies, convenience and gas stores, car washes, home improvement stores, grocery stores, professional services as well as general retail tenants.